Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models

Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP

(2014) L. E. Perez et al.   JOURNAL OF IMMUNOLOGY

Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency

(2012) Guo Wei et al.   CANCER CELL

NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1

(2012) A Craxton et al.   CELL DEATH AND DIFFERENTIATION

Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells

(2011) A. Natoni et al.   MOLECULAR CANCER THERAPEUTICS

Molecular architecture of the DNA replication origin activation checkpoint

(2010) Slavica Tudzarova et al.   EMBO JOURNAL

How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells?

(2010) K. Labib   GENES & DEVELOPMENT

Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells

(2010) M. Baou et al.   HAEMATOLOGICA

Cdc7 Kinase Inhibitors: 5-Heteroaryl-3-Carboxamido-2-Aryl Pyrroles as Potential Antitumor Agents. 1. Lead Finding

(2010) Maria Menichincheri et al.   JOURNAL OF MEDICINAL CHEMISTRY

RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses

(2010) M. N. Saha et al.   MOLECULAR CANCER THERAPEUTICS

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

(2010) Douglas W McMillin et al.   NATURE MEDICINE

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

(2009) Andrew Conroy et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cdc7 as a potential new target for cancer therapy

(2009) S. Ito et al.   DRUG NEWS & PERSPECTIVES

Cdc7 kinase – A new target for drug development

(2009) Ronan Swords et al.   EUROPEAN JOURNAL OF CANCER

Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma

(2009) Lia E. Perez et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Expression, purification and use of recombinant annexin V for the detection of apoptotic cells

(2009) Susan E Logue et al.   Nature Protocols

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma

(2008) W. Xiong et al.   BLOOD

Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potential Antitumor Agents. 1. Synthesis and Structure–Activity Relationships

(2008) Ermes Vanotti et al.   JOURNAL OF MEDICINAL CHEMISTRY

First Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potent and Orally Active Antitumor Agents. 2. Lead Discovery†

(2008) Maria Menichincheri et al.   JOURNAL OF MEDICINAL CHEMISTRY

Preclinicalversusclinical drug combination studies

(2008) Ting-Chao Chou   LEUKEMIA & LYMPHOMA

A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity

(2008) Alessia Montagnoli et al.   Nature Chemical Biology